Regencell Bioscience Holdings Limited (RGC)

USD 4.84

(-0.62%)

Annual Income Statements

(In USD)
Breakdown 2024 2023 2022 2021 2020 2019
Revenue - - - - - -
Cost of Revenue 745.58 Thousand 769.68 Thousand 604.39 Thousand 26.45 Thousand 9516.00 -
Gross Profit -745.58 Thousand -769.68 Thousand -604.39 Thousand -26.45 Thousand -9516.00 -
Operating Expenses 3.99 Million 6.27 Million 7.61 Million 1.38 Million 812.37 Thousand 390.99 Thousand
Selling, General and Administrative Expenses 2.92 Million 4.69 Million 5.1 Million 943.03 Thousand 426.14 Thousand 162.76 Thousand
Research and Development Expenses 1.06 Million 1.58 Million 2.51 Million 438.32 Thousand 386.23 Thousand 228.22 Thousand
Other Expenses - 211.34 Thousand 23.21 Thousand 34.61 Thousand - -
Cost and Expenses 4.73 Million 6.27 Million 7.61 Million 1.38 Million 812.37 Thousand 390.99 Thousand
Operating Income -4.73 Million -6.27 Million -7.61 Million -1.38 Million -812.37 Thousand -390.99 Thousand
Interest Expense - - - - - -
Income Tax Expense 312.12 Thousand -191.19 Thousand -171.82 Thousand -210.1 Thousand -1.00 -390.99
Earnings before Tax -4.36 Million -6.06 Million -7.59 Million -1.34 Million -812.37 Thousand -390.99 Thousand
Net Income -4.3 Million -5.87 Million -7.42 Million -1.34 Million -812.37 Thousand -390.99 Thousand
Earnings Per Share Basic -0.33 -0.45 -0.57 -0.11 -0.06 -0.03
Earnings Per Share Diluted -0.33 -0.45 -0.57 -0.11 -0.06 -0.03
Weighted Average Shares Outstanding 13.01 Million 13.01 Million 13.01 Million 12.64 Million 12.64 Million 12.64 Million
Weighted Average Shares Outstanding (Diluted) 13.01 Million 13.01 Million 13.01 Million 12.64 Million 12.64 Million 12.64 Million
Gross Margin - - - - - -
EBIT Margin - - - - - -
Profit Margin - - - - - -
EBITDA -3.61 Million -5.29 Million -6.99 Million -1.35 Million -802.85 Thousand -390.99 Thousand
Earnings Before Tax Margin - - - - - -

Income Statement Charts